Cargando…

Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia

PURPOSE: There are no comprehensive guidelines for the use of FDG PET in the following three clinical scenarios: (1) diagnostic work-up of patients with idiopathic Parkinson’s disease (PD) at risk of future cognitive decline, (2) discriminating idiopathic PD from progressive supranuclear palsy, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walker, Zuzana, Gandolfo, Federica, Orini, Stefania, Garibotto, Valentina, Agosta, Federica, Arbizu, Javier, Bouwman, Femke, Drzezga, Alexander, Nestor, Peter, Boccardi, Marina, Altomare, Daniele, Festari, Cristina, Nobili, Flavio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061481/ https://www.ncbi.nlm.nih.gov/pubmed/29779045 http://dx.doi.org/10.1007/s00259-018-4031-2

Ejemplares similares

Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia
por: Bouwman, Femke, et al.
Publicado: (2018)

Differences in Striatal Metabolism in [(18)F]FDG PET in Parkinson’s Disease and Atypical Parkinsonism
por: Seiffert, Alexander P., et al.
Publicado: (2022)

Diagnostic accuracy of cerebral [(18)F]FDG PET in atypical parkinsonism
por: Houssein, Naba Jawad, et al.
Publicado: (2023)

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Chiotis, Konstantinos, et al.
Publicado: (2021)

Editorial: Biomarkers of non-motor symptoms in Parkinson's disease and parkinsonisms
por: Filippi, Massimo, et al.
Publicado: (2023)

Multiclass classification of FDG PET scans for the distinction between Parkinson's disease and atypical parkinsonian syndromes()()
por: Garraux, Gaëtan, et al.
Publicado: (2013)

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Bischof, Gérard N, et al.
Publicado: (2021)

Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting
por: Perani, Daniela, et al.
Publicado: (2014)

Utility of 18F FDG-PET in Parkinsonism in an African population
por: Amod, Ferzana Hassan, et al.
Publicado: (2022)

Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review
por: Filippi, Massimo, et al.
Publicado: (2022)

Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
por: Altomare, Daniele, et al.
Publicado: (2021)

A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis
por: Daniela, Perani, et al.
Publicado: (2014)

Erratum to “A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis”
por: Perani, Daniela, et al.
Publicado: (2014)

Radiomics and supervised machine learning in the diagnosis of parkinsonism with FDG PET: promises and challenges
por: Peng, Shichun, et al.
Publicado: (2020)

Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age
por: Lauretani, Fulvio, et al.
Publicado: (2021)

Atypical parkinsonism: an update
por: Stamelou, Maria, et al.
Publicado: (2013)

Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy
por: Brumberg, Joachim, et al.
Publicado: (2020)

Predicting cognitive decline in Parkinson’s disease using FDG-PET–based supervised learning
por: Booth, Samuel, et al.
Publicado: (2022)

Brain activity of the emotional circuit in Parkinson’s disease patients with freezing of gait
por: Sarasso, Elisabetta, et al.
Publicado: (2021)

Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer’s disease: an expert opinion and practical guideline
por: Filippi, Massimo, et al.
Publicado: (2023)

Orthostatic Hypotension in Patients with Parkinson's Disease and Atypical Parkinsonism
por: Fereshtehnejad, Seyed-Mohammad, et al.
Publicado: (2014)

Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms
por: Santaella, Anna, et al.
Publicado: (2020)

Plasma Metabolite Markers of Parkinson’s Disease and Atypical Parkinsonism
por: Pathan, Meerakhan, et al.
Publicado: (2021)

Retinal Structure Abnormalities in Parkinson’s Disease and Atypical Parkinsonism
por: Ma, Xinxin, et al.
Publicado: (2023)

Atypical Ubiquitination and Parkinson’s Disease
por: Buneeva, Olga, et al.
Publicado: (2022)

Attentional Set-Shifting Deficit in Parkinson’s Disease Is Associated with Prefrontal Dysfunction: An FDG-PET Study
por: Sawada, Yoichi, et al.
Publicado: (2012)

Clinical validity of increased cortical uptake of [(18)F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
por: Wolters, E. E., et al.
Publicado: (2021)

Molecular Imaging of the GABAergic System in Parkinson’s Disease and Atypical Parkinsonisms
por: Terkelsen, Miriam H., et al.
Publicado: (2022)

Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism Syndromes
por: Lin, Chin-Hsien, et al.
Publicado: (2018)

The diagnostic potential of multimodal neuroimaging measures in Parkinson's disease and atypical parkinsonism
por: Park, Chang‐hyun, et al.
Publicado: (2020)

The Genetic Landscape of Parkinsonism-Related Dystonias and Atypical Parkinsonism-Related Syndromes
por: Diez-Fairen, Monica, et al.
Publicado: (2021)

FDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage disease
por: Matthews, Dawn C., et al.
Publicado: (2018)

PET/CT in Multiple Myeloma: Beyond FDG
por: Matteucci, Federica, et al.
Publicado: (2021)

A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism
por: Niccolini, Flavia, et al.
Publicado: (2016)

Progressive brain atrophy and clinical evolution in Parkinson’s disease
por: Filippi, Massimo, et al.
Publicado: (2020)

MRI biomarkers of freezing of gait development in Parkinson’s disease
por: Sarasso, Elisabetta, et al.
Publicado: (2022)

Quantitative susceptibility mapping in atypical Parkinsonisms
por: Mazzucchi, Sonia, et al.
Publicado: (2019)

Atypical Gait Cycles in Parkinson’s Disease
por: Ghislieri, Marco, et al.
Publicado: (2021)

Machine learning identified an Alzheimer’s disease-related FDG-PET pattern which is also expressed in Lewy body dementia and Parkinson’s disease dementia
por: Katako, Audrey, et al.
Publicado: (2018)

An atypical sarcoidosis involvement in FDG PET/CT: A case report
por: Robin, Philippe, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3p4dsaclsk774rg736ta9hnstj